+2 more
For this patient treatment of carbomazole 10 mg TID, propanalol 40 mg BD for 33 days this can be continued for 1 month same or not
Reading File
Finding Sources
Finding Sources
Searching PubMed
carbimazole hyperthyroidism treatment monitoring
Reading File
Reading File
Finding Sources
I now have comprehensive information to give a thorough, evidence-based analysis. Let me compile the complete answer.
Patient Summary - Mr. Mallesh, 56 Year Male
Reports reviewed (dated 5-11 May 2026):
| Test | Result | Reference |
|---|---|---|
| T3 | >651.0 µg/dL | 80-200 |
| T4 | >24.86 µg/dL | 5.1-14.3 |
| TSH | <0.005 µIU/mL | 0.27-4.20 |
| Anti-TPO | 21.63 IU/mL | <60 (normal) |
| Hb | 11.2 g% | 12.0-18.0 (low) |
| Platelets | 1,22,000 | 1,50,000-4,00,000 (low) |
| WBC | 9,000 | Normal |
| Total Bilirubin | 1.2 mg/dL | 0.2-1.0 (mildly elevated) |
| ALP | 211 U/L | 40-120 (significantly elevated) |
| Serum Creatinine | 0.6 mg/dL | Normal |
| eGFR | 101 mL/min | Normal |
| USG Neck | Bilateral thyromegaly, multiple cystic foci | ? Colloid goitre |
Diagnosis
This patient has severe overt hyperthyroidism (T3 and T4 massively elevated, TSH completely suppressed), most consistent with Graves' disease or toxic multinodular goitre with bilateral thyromegaly (anti-TPO is negative, but TRAb was not tested). MRI of neck was advised and is pending.
Can Carbimazole 10 mg TID + Propranolol 40 mg BD Be Continued for Another Month?
The Short Answer: Yes, the same regimen can be continued, but with important caveats and monitoring adjustments.
1. Carbimazole Dosing - Is 10 mg TID Appropriate?
Carbimazole 10 mg TID = 30 mg/day total, which is the correct starting dose for severe hyperthyroidism (T3/T4 >2x upper limit of normal, which this patient clearly has).
- Harrison's (22nd Ed.) states: "The initial dose of carbimazole or methimazole is usually 10-20 mg every 12 h... Treatment is reviewed 4-6 weeks after starting, and dose is titrated based on unbound T4 levels. Most patients do not achieve euthyroidism until 6-8 weeks after treatment is initiated."
- Since the patient is only 33 days into treatment, he is likely still approaching euthyroid state. Do not reduce the dose yet - continue 30 mg/day.
2. Propranolol 40 mg BD - Appropriate to Continue?
Propranolol is used to control adrenergic symptoms (palpitations, tremor, anxiety, tachycardia) in hyperthyroidism. It is continued until the patient is euthyroid and symptomatic relief is achieved. At 33 days, symptoms may still persist because thyroid levels remain elevated. Continue until the patient is clinically and biochemically euthyroid.
RED FLAGS in This Patient's Reports - Action Required
These findings CANNOT be ignored before simply continuing the prescription:
A. Thrombocytopenia (Platelets 1,22,000 - Low)
- Normal range: 1,50,000-4,00,000
- Carbimazole can rarely cause thrombocytopenia as a haematological side effect
- Also, hyperthyroidism itself can cause mild platelet reduction
- Action: Repeat CBC at 1-month follow-up. If platelets fall further, stop carbimazole and consider PTU or radioiodine.
B. Mild Anaemia (Hb 11.2 g%)
- Below male reference range (12-18 g%)
- Could be hyperthyroidism-related or a separate cause
- Peripheral smear is normocytic normochromic - suggests anaemia of chronic disease or early nutritional
- Action: Monitor; add iron/B12/folate if deficiency confirmed
C. Elevated ALP 211 U/L (Normal <120)
- This is significantly elevated - almost double the upper limit
- Carbimazole can cause hepatotoxicity (hepatitis, cholestasis)
- Hyperthyroidism itself can also elevate ALP (bone turnover, thyrotoxic hepatopathy)
- ALT (24) and AST (28) are normal, GGT (43) is borderline - pattern suggests hepatic cholestasis or bone-origin ALP rather than hepatocellular damage
- Action: Must re-check LFT at 4 weeks. If ALP rises further or bilirubin worsens, discontinue carbimazole immediately.
D. Mildly Elevated Total Bilirubin (1.2, Normal 0.2-1.0)
- Indirect bilirubin 0.9 (Normal 0-0.6) - slightly elevated
- Could reflect mild haemolysis, thyrotoxic hepatopathy, or early drug effect
- Needs close monitoring
E. USG Shows Large Goitre with Cystic Foci - MRI Advised
- MRI of neck is pending - this is important before finalising long-term treatment plan (surgery vs radioiodine vs continued medical management)
Recommended Monitoring Schedule for Next Month
| Investigation | When | Why |
|---|---|---|
| TFT (T3, T4, TSH) | At 6 weeks from start (i.e., ~1 week from now) | To assess response - dose titration based on fT4 |
| CBC with differential | Now and at 4 weeks | Watch thrombocytopenia, check for agranulocytosis |
| LFT (ALT, AST, ALP, Bilirubin) | At 4 weeks | Carbimazole hepatotoxicity surveillance - ALP already elevated |
| Heart rate / BP | Every visit | Guide propranolol dose |
| TRAb (TSH receptor antibody) | Once | Differentiates Graves' from toxic nodular goitre; guides duration of therapy |
Important Warning Signs to Tell Patient
Per textbook guidelines, patients on carbimazole must be warned to seek immediate medical attention if they develop:
- Sore throat or fever - could indicate agranulocytosis (rare but life-threatening)
- Jaundice / dark urine / pale stools - hepatotoxicity
- Unusual bleeding or bruising - thrombocytopenia
Summary Decision
| Drug | Decision | Reason |
|---|---|---|
| Carbimazole 10 mg TID (30 mg/day) | Continue same dose | T3/T4 still massively elevated; too early to reduce; euthyroidism expected only by week 6-8 |
| Propranolol 40 mg BD | Continue | Symptomatic control still needed; taper only when euthyroid and asymptomatic |
| LFT recheck | Mandatory | ALP significantly elevated; must rule out drug hepatotoxicity |
| CBC recheck | Mandatory | Thrombocytopenia present; agranulocytosis risk |
| MRI Neck | Complete as advised | Bilateral thyromegaly with cystic foci - need to evaluate for malignancy and plan definitive therapy |
Clinical note: This analysis is based on the lab reports provided and standard textbook protocols (Harrison's Principles 22nd Ed., Scott-Brown's Otorhinolaryngology, Bailey & Love's Surgery). The treating physician should review the patient clinically, assess for symptoms of toxicity, and make the final prescribing decision. The elevated ALP and low platelets deserve careful follow-up before any routine repeat of the same prescription.
This is a shared conversation. Sign in to Orris to start your own chat.